

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. DECLE55.1C2CD1	APPLICATION NO. UNKNOWN
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANTS Moser, et al.	
		FILING DATE HEREWITH	GROUP ART UNIT UNKNOWN

JC996 U.S. PTO  
 10/072425  
 02/07/02

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
<i>[Signature]</i>	Supplementary European Search Report, dated June 13, 2001, from Application No. EP96911493. <i>Meyer, W.</i>


H:\DOCS\MRB\MRB-2838.DOC:SG  
 020702

EXAMINER	<i>[Signature]</i> 3/5/03	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.		

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
DECL55.1C2CD1APPLICATION NO.  
10/072,425INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT  
Moser et al.FILING DATE  
February 7, 2002GROUP  
UnknownRECEIVED  
JUN 13 2002

TECH CENTER 1600/2300



(USE SEVERAL SHEETS IF NECESSARY)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>[Signature]</i>	4,675,295	6/23/87	Osawa et al.			
	4,711,842	12/8/87	Taniyama et al.			
	4,950,598	8/21/90	Engleman et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 93/20185	10/14/93	PCT				
	WO 94/02156	2/3/94	PCT				
	WO 95/28479	10/26/95	PCT				
	WO 94/21808	9/29/94	PCT				
	WO 93/20186	10/14/93	PCT				
	WO 91/13632	9/19/91	PCT				

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
<i>[Signature]</i>	Guo et al. <u>Science</u> , Vol. 263, Jan. 28, 1994. "Effective Tumor Vaccine Generated by Fusion of Hepatoma Cells with Activated B Cells", pp 518-520.
	Paglia et al. <u>Journal of Experimental Medicine</u> , Vol. 178, Dec. 1993. "Immortalized Dendritic Cell Line Fully Competent in Antigen Presentation Initiates Primary T Cell Responses in Vivo", pp 1893-1901
	Markowitz et al. <u>Journal Clinical Investigation</u> , Vol. 85, Mar. 1980. "Granulocyte-Macrophage Colony-Stimulating Factor Promotes Differentiation and Survival of Human Peripheral Blood Dendritic Cells IN VITRO", pp 955-961
	Inaba et al. <u>Journal of Experimental Medicine</u> , Vol. 172, Aug. 1990. "Dendritic Cells Pulsed with Antigens In Vitro Can Prime Antigen-specific, MHC-restricted T Cells in Situ", pp 631-640
	Hauser et al. <u>Proceeding National Academy of Sciences</u> , Vol. 85, Aug. 1988. "Activation and Expansion of Hapten- and Protein Specific T Helper Cells from Nonsensitized Mice", pp 5625-5628
	Zitvogel et al. <u>Journal of Experimental Medicine</u> , Vol. 183, Jan. 1996. "Therapy of Murine Tumors with Peptide-Pulsed Dendritic Cells: Dependence on T Cells, B7 Costimulation, and T Helper Cell 1-Associated Cytokines", pp 87-97
	Grabbe et al. <u>Journal of Immunology</u> , Vol. 146, May 15, 1991, "Tumor Antigen Presentation by Murine Epidermal Cells", pp 3656-3661.
	Steinman, <u>Annual Review of Immunology</u> , Vol. 9, 1991. "The Dendritic Cell System and its Role in Immunogenicity", pp 271-296.
	Inaba et al. <u>Journal of Experimental Medicine</u> , Vol. 176, Dec. 1992. "Generation of Large Numbers of Dendritic Cells from Mouse Bone Marrow Cultures Supplemented with Granulocyte Colon-Stimulating Factor", pp 1693-1702
	Inaba et al. <u>Journal of Experimental Medicine</u> , Vol. 175, May 1992. "Identification of Proliferating Dendritic Cell Precursors in Mouse Blood", pp 1157-1167
<i>[Signature]</i>	Razi-Wolf et al. "Evidence for an Additional Ligand, Distinct from B7, for the CTLA-4 Receptor, 1993, <u>Proceedings National Academy of Sciences, USA</u> Volume 90, Issue 23, pp. 11182-11186, dated December 1, 1993.

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
DECLE55.1C2CD1APPLICATION NO.  
10/072,425INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Moser et al.FILING DATE  
February 7, 2002GROUP  
UnknownRECEIVED  
JUN 11 2002  
TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
1/32	Hathcock et al., "Identification of an Alternative CTLA-4 Ligand Costimulatory for T Cell Activation," <u>Science</u> , Volume 262, pp. 905-907, dated November 1993.
	Young, et al., "Dendritic Cells as Adjuvants for Class I Major Histocompatibility Complex-restricted Antitumor Immunity, <u>Journal of Experimental Medicine</u> Volume 183, pp. 7-11, dated January 1996.
	Grabbe et al., "Dendritic Cells as Initiators of Tumor Immune Responses: A Possible Strategy for Tumor Immunotherapy? <u>Immunology Today</u> , Volume 16, No. 3, pp. 117-121 (1995).
	Ramarathnam et al., "T Cell Costimulation by B7/BB1 Induces CD8 T Cell-Dependent Tumor Rejection: An Important Role of B7/BB1 in the Induction, Recruitment, and Effector Function of Antitumor T Cells, <u>Journal of Experimental Medicine</u> , Volume 179, pp. 1205-1214, dated April 1994.
	Knight et al., "Influence of Dendritic Cells on Tumor Growth" <u>Proceedings National Academy of Sciences</u> , Volume 82, Issue 13, pp. 4495-4497, dated July 1, 1985.
	Flamand et al., "Murine Dendritic Cells Pulsed in vitro with Tumor Antigen Induce Tumor Resistance in vivo, <u>European Journal of Immunology</u> Volume 24, pp. 605-610 (1994).
	Paglia et al., "Murine Dendritic Cells Loaded in Vitro with Soluble Protein Prime Cytotoxic T Lymphocytes Against Tumor Antigen in Vivo, <u>Journal of Experimental Medicine</u> , Volume 183, pp. 317-322, dated January 1996.
	Ossevoort et al., "Dendritic Cells as Carriers for a Cytotoxic T-Lymphocyte Epitope-Based Peptide Vaccine in Protection Against a Human Papillomavirus Type 16-Induced Tumor, <u>Munotherapy</u> , Volume 18, pp. 86-94 (1995).
	Mayordomo et al., "Bone Marrow-Derived Dendritic Cells Pulsed with Synthetic Tumor Peptides Elicit Protective and Therapeutic Antitumor Immunity, <u>Nature Medicine</u> , Volume 1, pp. 1297-1302, dated December 1995.
	Stuhler, et al., "Recruitment of Helper T Cells...", <u>Cancer Immunol Immunother</u> , 1994, 39: 342-345
	Breel, et al., "Murine Hybrid Cell Lines...", <u>Immunobiology</u> , Vol. 178, pp. 167-176, 1988
1/32	Ellis, J., et al. (1991) Antigen Presentation by Dendritic Cells Provides Optimal Stimulation for the Production of Interleukin (IL)2, IL4 and Interferon - $\gamma$ by Allogenic T Cells. <u>European Journal of Immunology</u> . 21: 2803-2889

H:\DOCS\MRB\MRB-2973.DOC:ss  
041902

EXAMINER	1/32 3/15/02	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>		